BioMarin Pharmaceutical Inc (BMRN) - Financial and Strategic SWOT Analysis Review

Date: April 11, 2018
Pages: 62
Price:
US$ 125.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: BDF56652184EN
Leaflet:

Download PDF Leaflet

BioMarin Pharmaceutical Inc (BMRN) - Financial and Strategic SWOT Analysis Review
BioMarin Pharmaceutical Inc (BMRN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

BioMarin Pharmaceutical Inc (BioMarin) is a biopharmaceutical company which develops and commercializes innovative pharmaceuticals for treatment of serious diseases and medical conditions such as Kyndrisa (drisapersen), Duchenne muscular dystrophy (DMD), phenylketonuria (PKU), achondroplasia, late infantile neuronal ceroid lipofuscinosis (CLN2) and hemophilia A. Its product portfolio consists of products and multiple clinical and preclinical product candidates. The company operates through its manufacturing facilities in Novato, California and has its presence in US, Europe, Latin America, the Middle East, and Asia-Pacific. BioMarin is headquartered in San Rafael, California, the US.

BioMarin Pharmaceutical Inc Key Recent Developments

Feb 22,2018: BioMarin Reports Fourth Quarter 2017 Financial Results
Feb 05,2018: BioMarin Announces 20 Presentations at 14th Annual WORLDSymposium 2018
Dec 14,2017: Gene therapy success could lead to cure for haemophilia
Dec 09,2017: New Therapies Improve Outlook for Bleeding and Clotting Disorders
Oct 26,2017: BioMarin Announces Third Quarter 2017 Financial Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

NOTE: Out of security concerns GlobalData requires using corporate email address.
SECTION 1 - ABOUT THE COMPANY

BioMarin Pharmaceutical Inc - Key Facts
BioMarin Pharmaceutical Inc - Key Employees
BioMarin Pharmaceutical Inc - Key Employee Biographies
BioMarin Pharmaceutical Inc - Major Products and Services
BioMarin Pharmaceutical Inc - History
BioMarin Pharmaceutical Inc - Company Statement
BioMarin Pharmaceutical Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture

SECTION 2 – COMPANY ANALYSIS

Company Overview
BioMarin Pharmaceutical Inc - Business Description
Product Category: Aldurazyme (laronidase)
Overview
Performance
Product Category: Brineura (cerliponase alfa)
Overview
Performance
Product Category: Firdapse
Overview
Performance
Product Category: Kuvan (sapropterin hydrochloride)
Overview
Performance
Product Category: Naglazyme (galsulfase)
Overview
Performance
Product Category: Vimizim (elosulfase alfa)
Overview
Performance
Geographical Segment: Europe
Performance
Geographical Segment: Latin America
Performance
Geographical Segment: Rest of the World
Performance
Geographical Segment: United States
Performance
BioMarin Pharmaceutical Inc - Corporate Strategy
BioMarin Pharmaceutical Inc - SWOT Analysis
SWOT Analysis - Overview
BioMarin Pharmaceutical Inc - Strengths
BioMarin Pharmaceutical Inc - Weaknesses
BioMarin Pharmaceutical Inc - Opportunities
BioMarin Pharmaceutical Inc - Threats
BioMarin Pharmaceutical Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
BioMarin Pharmaceutical Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Feb 05, 2018: BioMarin Announces 20 Presentations at 14th Annual WORLDSymposium 2018
Dec 14, 2017: Gene therapy success could lead to cure for haemophilia
Dec 09, 2017: New Therapies Improve Outlook for Bleeding and Clotting Disorders
Oct 26, 2017: BioMarin Announces Third Quarter 2017 Financial Results
Oct 18, 2017: BioMarin Highlights Breadth of Innovative Development Pipeline at R&D Day on October 18th in New York
Oct 11, 2017: BioMarin to Highlight Breadth of Innovative Development Pipeline at R&D Day on October 18th in New York
Oct 03, 2017: BioMarin Appoints Robert J. Hombach, Former Baxalta CFO and COO, to Board of Directors
Aug 02, 2017: BioMarin Announces Second Quarter 2017 Financial Results
May 04, 2017: BioMarin Announces First Quarter 2017 Financial Results
Feb 23, 2017: BioMarin Announces Fourth Quarter and Full Year 2016 Financial Results

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

BioMarin Pharmaceutical Inc, Key Facts
BioMarin Pharmaceutical Inc, Key Employees
BioMarin Pharmaceutical Inc, Key Employee Biographies
BioMarin Pharmaceutical Inc, Major Products and Services
BioMarin Pharmaceutical Inc, History
BioMarin Pharmaceutical Inc, Subsidiaries
BioMarin Pharmaceutical Inc, Joint Venture
BioMarin Pharmaceutical Inc, Key Competitors
BioMarin Pharmaceutical Inc, Ratios based on current share price
BioMarin Pharmaceutical Inc, Annual Ratios
BioMarin Pharmaceutical Inc, Annual Ratios (Cont.1)
BioMarin Pharmaceutical Inc, Interim Ratios
BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
BioMarin Pharmaceutical Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

LIST OF FIGURES

BioMarin Pharmaceutical Inc, Performance Chart (2013 - 2017)
BioMarin Pharmaceutical Inc, Ratio Charts
BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

COMPANIES MENTIONED

Tesaro Inc
Shire Plc
Protalix BioTherapeutics Inc
Genzyme Corp
Enzon Pharmaceuticals Inc
BioSpecifics Technologies Corp
Biogen Inc
Amicus Therapeutics Inc
Skip to top


Ask Your Question

BioMarin Pharmaceutical Inc (BMRN) - Financial and Strategic SWOT Analysis Review
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: